Tolerability and patient/physician satisfaction with subcutaneously administered methotrexate provided in two formulations of different drug concentrations in patients with rheumatoid arthritis

Open Rheumatology Journal

Volumn 4, Issue , 2010, Pages 15-22

  Müller Ladner, Ulf ^a   Rockwitz, Karin ^b   Brandt Jürgens, Jan ^c   Haux, Roland ^c   Kästner, Peter ^d   Braun, Jürgen ^e   Demary, Winfried ^f   Guimbal Schmolck, Cécile ^g   Pichlmeier, Uwe ^g   Brandt, Andreas ^g  

^a KERCKHOFF HEART CENTER   (Germany)

^b Practising Rheumatologist   (Germany)

^c Practising Rheumatologist   (Germany)

^d Practising Rheumatologist   (Germany)

^e RHEUMAZENTRUM RUHRGEBIET   (Germany)

^f Practising Rheumatologist   (Germany)

^g MEDAC GMBH   (Germany)

Author keywords

Methotrexate; Prefilled syringe; Rheumatoid arthritis; Subcutaneous injection

Indexed keywords

METHOTREXATE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CERVICAL ROOT PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG ADMINISTRATION ROUTE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FACE FRACTURE; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL DISEASE; HUMAN; INJECTION SITE IRRITATION; LEUKOCYTE COUNT; LIMB NECROSIS; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MUCOSAL DRYNESS; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NECROSIS; NERVE ROOT LESION; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYRINGE; VERTIGO; VISUAL ANALOG SCALE;

EID: 77953373800     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/1874312901004010015     Document Type: Article

References (9)

1. Balis FM, Mirro J, Jr., Reaman GH, et al. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988; 6: 1882-6.
2. Brooks PJ, Spruill WJ, Parish RC, Birchmore DA. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 91-4.
3. Sander O, Hübner G, Rau R. Subcutaneous MTX - a reasonable addition of established modes of administration. Z Rheumatol 1996; 55(Suppl 1): 111.
4. Zackheim HS. Subcutaneous administration of methotrexate. J Am Acad Dermatol 1992; 26: 1008.
5. Braun J, Kästner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008; 58: 73-81.
6. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
7. Wollenhaupt J, Alten R, Backhaus M, et al. Recommendations for the treatment of rheumatoid arthritis. Results from a German consensus conference: Update 2009. Akt Rheumatol 2009; 34: 234-9.
8. Pavy S, Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: Clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006; 73: 388-95.
9. Tarner IH, Manger B, Fleck M, et al. Evidence-based recommendations of a national group of experts on the use of methotrexate in inflammatory rheumatic diseases. Akt Rheumatol 2009; 34: 59-66